Ablynx

• Netherlands-based Avidicure has secured $50 million in seed financing to develop its AVC-Boosters platform, a novel multifunctional antibody modality designed to harness both innate and adaptive immune responses against cancer. • The company's lead product, AVC-S-101, targets Trop2 protein and is being developed for non-small cell lung cancer and other indications, with potential to deliver targeted and potent cancer monotherapy with reduced toxicity. • Avidicure's platform leverages decades of antibody engineering expertise and offers plug-and-play functionality for multiple product development, positioning it to potentially surpass first-generation antibodies, checkpoint inhibitors, and ADCs.

Avidicure Launches with $50M to Develop Novel Multifunctional Antibody Platform for Cancer